Dr. Bozik is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2100 Wharton St
Ste 615
Pittsburgh, PA 15203Phone+1 412-488-1776Fax+1 412-488-8487
Education & Training
UPMC Medical Education (Pittsburgh)Residency, Neurology, 1990 - 1992- UPMC Medical EducationResidency, Pathology-Anatomic and Clinical, 1989 - 1990
University of MichiganResidency, Neurology, 1988 - 1989- UPMC Medical Education (Mercy)Internship, Transitional Year, 1987 - 1988
University of Pittsburgh School of MedicineClass of 1987
Certifications & Licensure
PA State Medical License 1989 - 2014- American Board of Psychiatry and Neurology Neurology
Publications & Presentations
PubMed
- 133 citationsThe effects of dexpramipexole (KNS-760704) in individuals with amyotrophic lateral sclerosisMerit Cudkowicz, Michael E. Bozik, Evan Ingersoll, Robert G. Miller, Hiroshi Mitsumoto
Nature Medicine. 2011-12-01 - 174 citationsDexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trialMerit Cudkowicz, Leonard H. van den Berg, Jeremy M. Shefner, Hiroshi Mitsumoto, Jesus S. Mora
The Lancet. Neurology. 2013-11-01 - 67 citationsBrain Tumor Volume Measurement: Comparison of Manual and Semiautomated MethodsBonnie N. Joe, Melanie B. Fukui, Carolyn C. Meltzer, Qingshou Huang, Roger S. Day
Radiology. 1999-09-01
Press Mentions
Knopp Biosciences Presents New Phase 2 Data at AAAAI 2022 Demonstrating That Oral Dexpramipexole Improves Airflow Obstruction as Measured by Forced Expiry Volume (FEV1), Largely Through Its Effect on Forced Vital Capacity (FVC)February 28th, 2022- Knopp Biosciences Presents New Phase 2 Data at ERS 2021 Demonstrating That Reduction in Eosinophil Count by Dexpramipexole Significantly Correlates with Improvement in Lung FunctionSeptember 7th, 2021
- Knopp Biosciences Reports Positive Results from the Phase 2 EXHALE Trial of Oral Dexpramipexole in Moderate-to-Severe Eosinophilic Asthma at ATS 2021May 17th, 2021
- Join now to see all
Grant Support
- Therapeutic Studies--Primary CNS MalignanciesNational Cancer Institute1996–1997
- Immunobiological Responses To RAT Brain Tumor VaccinesNational Cancer Institute1996–1997
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
